Novartis Advances Pluvicto and Actinium-Based Therapy in Prostate Cancer

Novartis AG (NYSE: NVS) on June 1, 2026, reported positive clinical progress for its radioligand therapy Pluvicto and an investigational actinium-based candidate, signaling an expanded footprint in prostate cancer treatment. Data presented at a medical conference showed both assets met key efficacy endpoints. Pluvicto, already approved for PSMA-positive metastatic castration-resistant prostate cancer, demonstrated a 38% reduction in disease progression risk in a new patient cohort. A Phase 1 trial of the actinium-based therapy, in-licensed via a partnership, achieved a 62% objective response rate in heavily pre-treated patients. The two programs target distinct tumor antigens, offering a complementary platform. Novartis shares rose 2.1% in early trading. The company said it plans to submit regulatory filings for expanded Pluvicto indications in the U.S. and Europe by late 2026, while accelerating the actinium program into mid-stage trials.